Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Phytogalactolipids triggered oxidative stress to inhibit drug-resistant colorectal cancer by suppressing interferon-α-induced protein 6.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ho Yi-Fang, Tsai Ya-Hsuan, Jian Ting-Yan, Lin Han-Huei, Shyur Lie-Fen, Chang Meng-Ting, Lin Alexander, Zhan You-Zhong, Lin Yu-Ling
Аннотация
BACKGROUND: Drug resistance is a major challenge in colorectal cancer (CRC) treatment. Overcoming drug resistance and improving therapeutic outcomes are crucial issues for patients with drug-resistant CRC. Crassocephalum rabens (Benth.) S. Moore (CR) is an edible plant and a folk medicine. Its galactolipids have anti-inflammatory and antitumor potential.
PURPOSE: This study explored the pharmacological mechanism and therapeutic efficacy of galactolipids isolated from CR (designated CRA) for treating drug-resistant CRC in vitro and in vivo.
METHODS: The antitumor activity and molecular mechanisms of CRA were investigated using cytotoxicity, reactive oxygen species (ROS) production, RNA sequencing, quantitative PCR (qPCR), Western blotting, and LPA concentration assays. Virtual molecular docking was conducted to identify CRA's action site on the target protein. The therapeutic effectiveness of CRA was evaluated using HT-29 xenograft mice.
RESULTS: CRA induced ROS-mediated cytotoxicity by inhibiting the expression of interferon-α-induced protein 6 (IFI6). IFI6 suppression by CRA led to ROS accumulation and oxidative DNA damage, ultimately resulting in cell death. CRA antagonistically targeted lysophosphatidic acid receptors (LPAR), specifically LPAR2, and blocked their downstream signaling pathways, including PI3K/AKT/mTOR, Ras/Raf/p38, PLC/PKC, Rho/PKA, and NF-κB, which inhibited cell survival. Furthermore, CRA also inhibited the intracellular synthesis of LPA. In HT-29 tumor-bearing mice, CRA significantly reduced tumor growth. The antitumor activity of CRA, through inhibiting LPAR2 expression and inducing IFI6-mediated oxidative stress, was also observed in tumors.
CONCLUSION: CR galactolipids directly targeted LPAR2, inhibited the LPAR2 signaling pathways, and induced IFI6-mediated ROS accumulation to combat drug-resistant CRC.
PURPOSE: This study explored the pharmacological mechanism and therapeutic efficacy of galactolipids isolated from CR (designated CRA) for treating drug-resistant CRC in vitro and in vivo.
METHODS: The antitumor activity and molecular mechanisms of CRA were investigated using cytotoxicity, reactive oxygen species (ROS) production, RNA sequencing, quantitative PCR (qPCR), Western blotting, and LPA concentration assays. Virtual molecular docking was conducted to identify CRA's action site on the target protein. The therapeutic effectiveness of CRA was evaluated using HT-29 xenograft mice.
RESULTS: CRA induced ROS-mediated cytotoxicity by inhibiting the expression of interferon-α-induced protein 6 (IFI6). IFI6 suppression by CRA led to ROS accumulation and oxidative DNA damage, ultimately resulting in cell death. CRA antagonistically targeted lysophosphatidic acid receptors (LPAR), specifically LPAR2, and blocked their downstream signaling pathways, including PI3K/AKT/mTOR, Ras/Raf/p38, PLC/PKC, Rho/PKA, and NF-κB, which inhibited cell survival. Furthermore, CRA also inhibited the intracellular synthesis of LPA. In HT-29 tumor-bearing mice, CRA significantly reduced tumor growth. The antitumor activity of CRA, through inhibiting LPAR2 expression and inducing IFI6-mediated oxidative stress, was also observed in tumors.
CONCLUSION: CR galactolipids directly targeted LPAR2, inhibited the LPAR2 signaling pathways, and induced IFI6-mediated ROS accumulation to combat drug-resistant CRC.